NCT03785249 2025-09-30
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Phase 1/2 Active not recruiting
Clinical Trials
3 trialsNCT05634525 2025-07-25
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04975256 2024-12-16
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Mirati Therapeutics Inc.
Phase 1 Terminated